Suven Life Sciences today said it has received two product patents for its new chemical entities (NCEs) used in treating disorders like Alzheimer's disease, Parkinson and Schizophrenia.
The company has received patents by the Indian Patent Office which are valid till 2027, Suven said in a filing to the Bombay Stock Exchange (BSE).
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS area that are being developed for cognitive disorders which has an estimated $30 billion market potential globally", Suven CEO Venkat Jasti said.
Products of these inventions may be out-licensed at various phases of clinical development like Phase-I or Phase-II, the company said in a statement.
With these new patents, Suven has a total of 11 granted Indian patents on new chemical entities.
Shares of Suven today closed at Rs 24.8 on the National Stock Exchange (NSE), up 2.48 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app